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Abstract
Purpose To evaluate the clinicopathological and immu-
nophenotypic characteristics of endometrial stromal sar-
coma (ESS) in China.
Methods and materials Seventy-two consecutive ESS
cases treated between 1995 and 2009 were retrospectively
reviewed.
Results Sixty-three patients received surgical treatment.
Forty-one patients underwent pelvic lymphadenectomy. In
paraffin-embedded specimens, expression of the following
molecular markers was detected: CD10 (27/36), vimentin
(37/38), HHF35 (3/32), S-100 (0/25), desmin (2/29),
CD117 (0/23), CD34 (2/24), alpha-inhibin (0/17), CK (1/
34), CD99 (4/9), smooth muscle actin (5/25), EMA (0/7),
estrogen receptor (13/16) and progesterone receptor (13/
16). CD10 and vimentin were expressed more frequently in
these specimens. Tumor classification, CD10 and surgical
procedures were significantly associated with disease-free
survival (DFS). Surgical procedures were significantly
associated with overall survival (OS). Tumor stage
(P = 0.024) and surgical procedure (P = 0.042) were
found to be significant independent prognostic factors for
DFS. No complete or partial response was observed among
patients who received radiotherapy or chemotherapy.
Conclusions Our results indicate that total hysterectomy
with bilateral salpingo-oophorectomy followed by pelvic
lymphadenectomy is associated with an improved treat-
ment outcome. CD10-negative expression may contribute
to the malignant characteristics and recurrence associated
with ESS.
Keywords Endometrial stromal sarcoma  Pelvic
lymphadenectomy  CD10  Prognosis
Introduction
Endometrial stromal sarcoma (ESS) is a rare uterine
malignancy that accounts for \0.5 % of all malignant
uterine tumors and for 7–17 % of uterine sarcomas [1, 2].
Traditionally, ESS is classified into low- and high-grade
subtypes based on its mitotic rate. Currently, ESS is divi-
ded into low-grade endometrial stromal sarcomas and
undifferentiated endometrial sarcoma (UES) according to
the 2003 World Health Organization Classification of
Tumors [3]. Its rarity and histological differences underlie
the difficulty in diagnosing ESS and the choice of sub-
sequent treatment strategies. Factors such as mitotic index,
size, clinical stage, histological grade, positive surgical
margins, menopause and age have been reported as
potential prognostic parameters, but their use in ESS
remains controversial [4, 5].
CD10, or commonly known as acute lymphoblastic
leukemia antigen, is a cell-surface neutral endopeptidase
that deactivates bioactive peptides [6, 7]. Recently, CD10
has been demonstrated to be present within a variety of
non-hematopoietic neoplasms, including the normal endo-
metrial stroma and ESS [8–10]. To identify possible
molecular markers that correlate with prognosis of ESS
patients, we analyzed retrospectively the immunohisto-
chemical results of ESS patients.
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This retrospective study aimed to evaluate the clinical
characteristics, immunophenotype, diagnosis, manage-
ment, and prognosis of ESS patients who were treated at
the Cancer Center, Sun Yat-sen University (Guangdong,
China) over a 15-year period.
Materials and methods
The Review Board of our Cancer Center of the Sun Yat-sen
University approved this study. All consecutive cases of
ESS diagnosed from 1995 to 2009 at the Cancer Center,
Sun Yat-sen University were reviewed. Data were retrieved
from medical records maintained in institutional databases.
The study only included patients diagnosed with ESS who
had been histologically confirmed based on WHO classi-
fication, and staged according to the International Federa-
tion of Gynecology and Obstetricsthe (FIGO) classification
(cases confirmed in foreign hospitals were all taken for
consultation with gynecological pathologists from Sun Yat-
sen University). Pathological diagnosis was conducted by
experienced pathologists of Sun Yat-sen University.
For patients who underwent complete resection, the
surgical procedure generally comprised total abdominal
hysterectomy with bilateral salpingo-oophorectomy and
pelvic lymphadenectomy. For incomplete resection
patients (partial or complete hysterectomy), bilateral sal-
pingo-oophorectomy and pelvic lymphadenectomy were
carried out. For patients suspected of common iliac or para-
aortic lymph node involvement, para-aortic lymph node
dissection was performed. Omentectomy was administered
for stage III ESS patients.
For patients with one of the following pathological risk
factors: incomplete resection for late-staged cases, positive
pelvic lymph nodes, vascular and lymphatic permeation
and UES, adjuvant radiotherapy and/or adjuvant chemo-
therapy was administered. The radiotherapy treatment
comprised external pelvic irradiation (18 MV X-rays) using
the multiportal technique; in one fraction of 1.8–2.0 Gy
daily, for a total dose of 50 Gy over 5–6 weeks.
Chemotherapy comprised one of the following combina-
tions as the primary drug for treatment: DDP (cisplatin)
(60–75 mg/m2, d1) ? cyclophosphamide (600–800 mg/m2,
d1-3) ? adriamycin (40–50 mg/m2, d1), DDP (60–75 mg/
m2, d1) ? adriamycin (40–50 mg/m2, d1) ? DTIC (dacar-
bazine) (200 mg/m2, d1-5), or ifosfamide (IFO) (1.5–2 g/m2,
d1-4) ? adriamycin (40–50 mg/m2, d1) ? Dacarbazine
(DTIC) (200 mg/m2, d1-5). Dosage was decreased when IV
degree bone marrow suppression occurred. In general, che-
motherapy was performed in 3–5 courses over a 3-week
period.
For each patient included in this study, the following
demographic and clinical data (last follow-up performed in
February, 2012) were obtained and listed: symptoms, age,
menopausal status, parity, family history of cancer, diag-
nosis procedure, tumor stage, surgical procedure, patho-
logical diagnosis, tumor size, lymphatic vascular space
invasion, depth of invasion, recurrent/metastatic sites,
chemotherapy history, radiotherapy history and hormonal
therapy history. Individual diagnosis for each case was
based on postoperative pathological results. Where recur-
rence was suspected, the corresponding patient’s diagnosis
was subject to identification by chest X-rays, a CT scan of
the chest and/or brain, and a PET-CT on the basis of a
physical examination. The time of diagnosis was defined as
the date of primary surgical procedure. The median dura-
tion of follow-up was 61.6 months (range,
15–185.6 months). OS was defined as the interval from
surgery to death from any cause. Status of patients was
confirmed at the date of last contact. DFS was defined as
the time interval from surgical resection to the first evi-
dence of recurrence or death from any cause, whichever
occurred first. Patients were examined at 2-month intervals
for the first 2 years, at 6-month intervals for the next
3 years and, thereafter, once a year. The primary end point
was any cancer-related death.
For immunostaining, 2 lm sections of tissue were cut
and mounted on glass slides. The sections were heated at
60 C for 2 h and deparaffinized in xylene and ethanol.
Antigen retrieval was performed using EDTA buffer
(1 mmol/L, pH 8.0) and boiled for 20 min in a microwave
oven, followed by treatment with 3 % H2O2 to block
endogenous peroxidase for 15 min at room temperature.
The slides were incubated at 4 C overnight antibody.
Antibody staining was done using ChemMateTM EnVi-
sionTM Detection Kit, Peroxidase/DAB, Rabbit/Mouse
(GeneTech, Shanghai, China). The sections were incubated
with horseradish peroxidase-conjugated secondary anti-
body (Zhong-shan Golden Bridge Biotech, Beijing, China)
for 30 min at room temperature. Hematoxylin was used for
counterstaining. Technical personnel of the pathology
department in our center performed all the immunohisto-
chemistry experiments. Two pathologists confirmed all the
results in a double-blind analysis. The pathological results
from the medical record library were further analyzed.
DFS and OS were estimated with the Kaplan–Meier
method and were compared by a log-rank test using
GraphPad Prism software (version 5, GraphPad Software).
Cox regression analysis of factors, including age, tumor
classification, tumor stage, lymphovascular space invasion,
depth of invasion, adjuvant therapy, surgical procedure and
CD10 expression, which were potentially related to sur-
vival, was used to identify independent factors that might
jointly have a significant effect on survival. All statistical
analyses were performed with SPSS 16.0 software. A
P value \0.05 was considered significant.




Seventy-nine consecutive ESS patients were treated at Sun
Yat-sen University, among which nine patients were
excluded because of insufficient follow-up data (for details,
see Tables 1, 2), and seven were excluded because they
were not diagnosed with ESS at the time immediately post-
transfer to Sun Yat-sen University following a non-standard
primary operation conducted at a foreign hospital. Among
the 63 cases taken for study, 50 (79.4 %) were treated pri-
marily at Sun Yat-sen University (including 29 patients
with complementary operation), and 13 (20.6 %) were
either referred to or were undergoing adjuvant therapy at
Sun Yat-sen University after the primary operation (with a
total hysterectomy baseline) and other adjuvant therapy.
Patients’ clinical and histopathological characteristics are
summarized in Table 3. The median age at diagnosis was
41.1 years (range: 19–61 years). Abnormal bleeding
(55.6 %) and pain (17.5 %) were the most frequent symp-
toms. Fifteen (23.8 %) patients were nulliparous and nine
(14.3 %) were postmenopausal at the time of diagnosis.
Thirteen (20.6 %) patients were preoperatively diagnosed
with ESS by dilation and curettage or other methods; the
remaining patients were diagnosed in or after surgery. The
median tumor size was 5.3 cm (range 2–11 cm) with rele-
vant data missing in 22 (34.9 %) patients. 51 (80.9 %)
patients were diagnosed as having low-grade ESS and 6
(14.6 %) as having UES. Within these 63 cases, the
majority (63.5 %) of patients’ disease stage was in stage I,
6.3 % stage II, 25.4 % stage III, and 4.8 % stage IV.
Table 1 General characteristics and treatments of 9 excluded ESS patients
Case Initial treatment (other hospitals) Replacement therapy (our hospital)
Age Treatment Pathology Recurrence
time (months)















15 Pelvic Untreated No No
4 47 Subtotal
hysterectomy





5 35 TAH Unknown 18 Vagina Vaginal tumor biopsy ESS No



















UES 1 Palliative operation No No
Table 2 Expression of genes in 9 excluded ESS patients




4 0 0 1 0 0 0 1 0 0 1 1
5 1 0 0 0
6 0 1 1 1 0 0 1 0
7
8 1
9 1 1 0 0 0 0 0 0 0 10 %
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Surgical procedure
Thirty-nine patients (61.9 %) underwent a total hysterec-
tomy with bilateral salpingo-oophorectomy, and pelvic
lymphadenectomy ± omentectomy/para-aortic lymph
node dissection, 13 patients (20.6 %) had a total hyster-
ectomy with bilateral salpingo-oophorectomy ± /para-
aortic lymph node dissection/omentectomy, and 11 patients
(17.5 %) had a total hysterectomy ± bilateral salpingo-
oophorectomy/pelvic lymphadenectomy/para-aortic lymph
node dissection/omentectomy, as part of surgical treatment.
Fifty-two (82.5 %) patients had a bilateral salpingo-
oophorectomy and 11 (17.5 %) did not; 41 (65.1 %)
patients had a pelvic lymphadenectomy and 22 (34.9 %)
did not.
After primary surgery, 52 patients (82.5 %) received
adjuvant therapy, 15 (23.8 %) were administered pelvic
radiation at 50 Gy, 48 (76.2 %) received chemotherapy, 11
(17.5 %) received chemotherapy plus radiotherapy, three
(4.8 %) received chemotherapy plus hormonal therapy, and
one (1.6 %) received radiotherapy plus hormonal therapy.
The 2-year DFS rate was 82.5 %, and the 5-year DFS rate
was 53.9 %. The median DFS duration was 53.8 months.
The 2-year OS rate was 93.6 %, and the 5-year OS rate was
60.3 %. The DFS and OS curves are shown in Fig. 1.
Recurrences
Recurrence developed in 13 (20.6 %) of the 63 patients,
resulting in 10 (15.7 %) reported deaths at the time of last
follow-up, with locations of recurrence as follows: pelvic
recurrence (6/13, 46.1 %), extrapelvic recurrence (2/13,
15.4 %) and both pelvic and extrapelvic recurrences (5/13,
38.5 %). Analysis of clinical data revealed that patients
diagnosed as having UES exhibited a significantly shorter
DFS (16.8 vs. 86.3 %; P = 0.0007) and OS (50 vs. 88.2 %;
P = 0.0234) compared to those having low-grade ESS.















Diagnostic dilatation and curettage 9 (14.3)
Hysteroscopic biopsy 2 (3.17)












Myometrium (unknown depth) 21







TAH ± BSO/OT/PL/PLND 11 (17.5)
TAH ? BSO ± /PL/OT 13 (20.6)
TAH ? BSO ? PL ± OT ± PLND 39 (61.9)
Hysterectomy
With BSO 52 (82.5)







Hormonal therapy 3 (4.7)




Chemotherapy and hormonal therapy 3 (4.8)
Radiotherapy and hormonal therapy 1 (1.6)
No adjuvant therapy 11 (17.5)
Distant metastasis and recurrence 13 (20.6)
Pelvic 6
Lung and bone 2
Pelvic and lung 5
TAH total abdominal hysterectomy, BSO bilateral salpingo-oopho-
rectomy, PL pelvic lymphadenectomy, OT omentectomy, PLND para-
aortic lymph node dissection, LVSI lymphatic vascular space invasion
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The 19 (30.2 %) patients in disease stages III–IV showed a
shorter DFS (68.4 vs. 84.1 %; P = 0.06) and OS (73.7 vs.
88.6 %; P = 0.0744) than the remaining 44 (69.8 %)
patients with stages I–II. Among the 63 patients, 41
(65.1 %) had previously undergone pelvic lymphadenec-
tomy, and six (9.5 %) were found to have nodal metastases.
Kaplan–Meier survival analyses showed that patients who
did not undergo a bilateral salpingo-oophorectomy had a
significantly shorter DFS (45.5 vs. 86.5 %; P = 0.0169)
and OS (54.5 vs. 90.4 %; P = 0.0475) than those who
received a bilateral salpingo-oophorectomy. Patients who
did not undergo a pelvic lymphadenectomy showed a
similar association with shorter DFS (54.5 vs. 92.7 %,
P = 0.001) and OS (63.6 vs. 95.1 %; P = 0.0025) than
patients who did receive a pelvic lymphadenectomy.
Patients who underwent a total hysterectomy with bilateral
salpingo-oophorectomy and pelvic lymphadenectomy dis-
played a significantly longer DFS (92.3 vs. 58.3 %,
P = 0.0038) and OS (94.9 vs. 66.7 %; P = 0.023) than
patients undergoing total hysterectomy ± salpingo-
oophorectomy/pelvic lymphadenectomy/para-aortic lymph
node dissection/omentectomy only. By contrast, patient
age, menopausal status, parity, tumor size, lymphatic vas-
cular space invasion, depth of invasion, and adjuvant
therapy did not show any significant association with DFS
or OS.
Molecular expression
For a subset of 46 cases, additional immunohistochemical
assays had been performed to detect the expression of
certain proteins, including CD10 (27/36), vimentin (37/38),
HHF35 (3/32), S-100 (0/25), desmin (2/29), CD117 (0/23),
CD34 (2/24), alpha-inhibin (0/17), CK (1/34), CD99 (4/9),
smooth muscle actin (5/25), EMA (0/7), estrogen receptor
(5 for 3?, 4 for 2?, 4 for 1?, 3 for 0), and progesterone
receptor (7 for 3?, 1 for 2?, 5 for 1?, 3 for 0). The Ki-67
proliferation index values were also available, and included
values of\30 % for 13 cases and C30 % for six cases. The
DFS values for those who were ki-67 positive (C30 %)
were 50 versus 76.9 % for those who were ki-67 negative
(\30 %) (P = 0.129) and overall survival was 66.7 vs.
84.6 % (P = 0.436), respectively. CD10-negative
Fig. 1 Survival curves for
overall survival (OS) and
disease-free survival (DFS)
associated with 63 patients
diagnosed with endometrial
stromal sarcoma ESS
Table 4 Correlations between CD10 expression and clinicopatho-
logical features of ESS patients






\50 21 16 (59.3) 5 (55.6) 1.0
C50 15 11 (40.7) 4 (44.4)
Menstruation status
Premenopausal 30 24 (88.9) 6 (66.7) 0.151
Postmenopausal 6 3 (11.1) 3 (33.3)
Parity
Multiparous 30 24 (88.9) 6 (66.7) 0.151
Nulliparous 6 3 (11.1) 3 (33.3)
Tumor size
C5 cm 17 14 (77.8) 3 (50) 0.307
\5 cm 7 4 (22.2) 3 (50)
Tumor’s classification
Low-grade ESS 28 25 (96.2) 3 (37.5) 0.001
UES 6 1 (3.8) 5 (62.5)
Tumor stage
I 22 18 (66.7) 7 (77.8) 0.69
II 3
III 9 9 (33.3) 2 (22.2)
IV 2
Depth of invasion
Mucous invasion 3 5 (38.5) 3 (50) 1
Myometrium 24
\ myometrium 5
[ myometrium 8 8 (61.5) 3 (50)
Serosal invasion 3
LVSI
Yes 9 8 (42.1) 1 (25) 1
No 14 11 (57.9) 3 (75)
Distant metastasis and recurrence
Yes 9 3 (11.1) 6 (66.7) 0.003
No 27 24 (88.9) 3 (33.3)
* Two-side Fisher’s exact test
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expression was significantly associated with tumor classi-
fication (P = 0.001), distant metastasis and recurrence
(P = 0.003), but was not significantly related to patient
age, menopausal status, parity, tumor size, lymphatic vas-
cular space invasion, or depth of invasion (Table 4).
Kaplan–Meier survival analyses showed that patients with
CD10-negative expression had a shorter DFS (33.3 vs.
88.9 %; P = 0.02) and OS (55.6 vs. 88.9 %; P = 0.11)
than those who were CD10-positive.
Univariate and multivariate analysis
Various clinicopathological variables were evaluated to
identify potential prognostic factors for survival. In uni-
variate analyses, death from ESS was associated with
surgical procedure (hazard ratio, 5.13; 95 % CI,
1.074–14.497; P = 0.04). This was also associated with
DFS (hazard ratio, 5.48; 95 % CI, 1.504–19.967;
P = 0.01). Additionally, recurrence from ESS was also
associated with tumor’s classification (hazard ratio, 6.047;
95 % CI, 1.925–18.996; P = 0.002) and CD10-negative
expression (hazard ratio, 4.696; 95 % CI, 1.049–21.015;
P = 0.043). However, upon multivariate Cox regression
analysis (including tumor stage, tumor’s classification and
surgical procedure), none of them remained as independent
predictors of OS (Table 5). Conversely, tumor stage
(P = 0.024) and surgical procedure (P = 0.042) were
found to be significant independent prognostic factors for
DFS.
Discussion
ESS are rare uterine malignancies that typically affect
women between 40 and 50 years of age and manifest
clinically through vaginal bleeding, [11] as exemplified in
this study, with the average age of the 63 patients being
41.1 years and vaginal bleeding being the most distinctive
symptom (55.6 %). Although early symptoms are often
observable in patients, many are diagnosed postoperatively
because of the decreased sensitivity of endometrial pipelle
for detecting ESS (only 13/63 patients were diagnosed with
ESS before surgical treatment in our study). Thus, 34/63
patients received a secondary operation following the first
(subtotal hysterectomy or total hysterectomy). The surgical
modality for ESS remains controversial. Although certain
gynecologic oncologists prefer that ESS be staged as
endometrial adenocarcinoma [12], some studies have
shown that including lymphadenectomy or ovarian pres-
ervation does not affect prognosis [13–15]. Conversely,
studies have found that recurrence does exist in patients
with retained ovaries [16, 17]. This high rate of recurrence
following a hysterectomy may in part be caused by estro-
gen stimulation originating from the retained ovaries. Our
data revealed that ovarian removal was effective in
delaying recurrences (P = 0.0169) and had a significant
effect on OS (P = 0.0475). ESS continues to be staged
according to FIGO guidelines for endometrial cancer;
therefore, initial complete staging would necessitate lymph
node sampling. A recent American series of 1010 ESS
patients showed that adding lymphadenectomy to hyster-
ectomy did not change the OS [18]. However, another
recent Canadian series showed a substantial lymph node
involvement rate in 33 % of ESS [19]. Cheng [20] found
that 22 % of patients who underwent pelvic lymphade-
nectomy had positive lymph nodes at surgery. In our study,
among 63 patients, 41 (65.1 %) previously underwent
pelvic lymphadenectomy, and six (9.5 %) were found to
have nodal metastases. We found that pelvic lymphade-
nectomy had a significant advantage both in DFS
(P = 0.001) and OS (P = 0.0025). Patients who under-
went total hysterectomy with bilateral salpingo-oophorec-
tomy and pelvic lymphadenectomy ± para-aortic lymph
node dissection/omentectomy presented a longer DFS
(P = 0.0038) and OS (P = 0.023), which could addition-
ally act as a significant independent prognostic factor of
DFS in ESS (P = 0.042). As such, we advocate the inte-
gration of pelvic lymphadenectomy and bilateral salpingo-
oophorectomy into a standardized operation.
While data support the use of chemotherapy in the
treatment of other sarcomas [21], very little data exist to
support its use in the treatment of ESS. The European
Organisation for Research and Treatment of Cancer
Gynaecological Cancer Group Study proposed a trial to
evaluate the treatment effect of adjuvant radiotherapy on
all uterine sarcoma types. However, this randomized study
failed to show any benefit of adjuvant RT in terms of OS
and DFS in patients with stage I or II sarcoma [22]. We-
itmann [23] previously proposed total hysterectomy and
bilateral salpingo-oophorectomy followed by adjuvant
radiation therapy as the most effective treatment for
patients. Presently, adjuvant hormonal therapy appears to
be used predominantly in ESS patients. Patients with pri-
mary residual or recurrent ESS were managed with hor-
monal therapy and showed an 82 % response rate with a
median duration of response of 48 months [24, 25]. After
comparing the status of patients who received chemother-
apy and or radiotherapy or chemotherapy ? radiotherapy
with those who received no additional treatment in all
stages, we determined no association between adjuvant
treatment and OS or DFS. Unfortunately, we were unable
to analyze cases for patients who accepted hormone ther-
apy after surgery, as outpatient records frequently did not
meet the review standards because of the limited number of
patients received, and the difficulty of follow-up.
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Developments in recent years have shown that immu-
nohistochemistry can be useful, not only in the differential
diagnosis, but also in the prognosis of tumors of the female
genital tract. Currently, however, no specific immunohis-
tochemical markers exist for the diagnosis of ESS. In our
study, the group of ESS cases expressed CD10, vimentin,
HHF35, desmin, CD34, CK, CD99, smooth muscle actin,
estrogen receptor, and progesterone receptor. In this series,
CD10 (27/36) and vimentin were expressed more fre-
quently. Expression of the cell differentiation marker CD10
was remarkably similar in all uterine sarcoma groups [26].
Recently, Oliva et al. [27] reported that although only 1 of
10 cases of endometrial stromal tumors were CD10-
positive, four out of four high-grade ESSs in the study by
Agoff et al. [28] and four of six high-grade ESSs in the
study by McCluggage et al. [9], were CD10-negative,
indicated that in high-grade ESS, decreased expression
may be related to tumor differentiation. Our study con-
sisted of 63 cases of ESS, out of which 13 progressed into
either pelvic recurrence or pulmonary metastases, or both.
Whether CD10-positive patients in our ESS cases truly
represent a longer OS or independent prognostic factor
cannot be ascertained, but CD10 did demonstrated signif-
icant association with the tumor’s classification
(P = 0.001) and recurrence (P = 0.003). In addition,
CD10-positive patients showed a longer DFS (P = 0.02).
Table 5 Cox regression analysis of various factors associated with disease-free survival and overall survival in ESS patients
Disease-free survival
Variables HR (95 % CI) Favorable/unfavorable P value
Univariate analysis
Age (years) 0.771 (0.237–2.509) \50/C50 0.661
Tumor’s classification 6.047 (1.925–18.996) Low-grade ESS/UES 0.002
Tumor stage 2.748 (0.909–8.18) I–II/III–IV 0.073
LVSI 4.239 (0.707–25.405) No/yes 0.114
Depth of invasion 2.602 (0.288–23.531) \ myometrium/[ myometrium 0.395
Surgical procedure 5.48 (1.504–19.967) B/A 0.01
Adjuvant therapy 2.349 (0.302–18.282) No/yes 0.415
CD10 4.696 (1.049–21.015) Positive/negative 0.043
Multivariate analysis
Tumor’s classification 3.068 (0.881–10.689) Low-grade ESS/UES 0.078
Tumor stage 3.789 (1.190–12.064) I–II/III–IV 0.024
Surgical procedure 4.489 (1.059–19.022) B/A 0.042
Overall survival
Variables HR (95 % CI) Favorable/unfavorable P value
Univariate analysis
Age (years) 1.472 (0.408–5.305) \50/C50 0.5555
Tumor’s classification 3.139 (0.731–13.48) Low-grade ESS/UES 0.124
Tumor stage 3.091 (0.888–10.759) I–II/III–IV 0.076
LVSI 4.066 (0.677–24.414) No/yes 0.141
Depth of invasion 1.963 (0.201–19.175) \ myometrium/[ myometrium 0.562
Surgical procedure 5.13 (1.074–14.497) B/A 0.04
Adjuvant therapy 1.641 (0.204–13.196) Yes/no 0.642
CD10 3.358 (0.675–16.707) Positive/negative 0.139
Multivariate analysis
Tumor’s classification 4.476 (0.962–20.812) Low-grade ESS/UES 0.056
Tumor stage 2.746 (0.562–13.409) I–II/III–IV 0.212
Surgical procedure 3.136 (0.587–16.748) B/A 0.181
* Two-side Fisher’s exact test
A TAH ± BSO/OT/PL/PLND
B TAH ? BSO ? PL ± OT ± PLND
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Although the level of CD10 (P = 0.033) expression
appears to be a useful prognostic factor in univariate
analysis, the limited range of our sample series did not
permit any definitive conclusions. CD10 may represent a
molecular marker that correlates with prognosis of ESS
patients. Other markers have also been studied, for exam-
ple, metalloproteinases, c-KIT, and CD34, all of which
proved been negative [29].
In conclusion, the results of the present study indicate
that FIGO stage and surgical procedure represent prog-
nostic factors for patient survival, thus total hysterec-
tomy ? bilateral salpingo-oophorectomy followed by
pelvic lymphadenectomy would likely result in an
improved treatment outcome, representing a factor worth
considering in the staging of surgery for ESS. CD10-neg-
ative status may contribute to the malignant characteristic
and recurrence associated with ESS, and may play a sig-
nificant role in molecular-targeted therapy.
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